Table 1.

Demographics and baseline disease characteristics

Total Patients		232		100%
Surgery done		08/02/91–12/13/12
Age at Diagnosis
< 60		130		56%
≥ 60		102		44%
Median (Range)		58 (26–89)
Tumor Histology
Serous Carcinoma		160		69%
Endometrioid Adenocarcinoma		21		9%
Clear Cell Carcinoma		17		7%
Mixed		15		6%
Mucinous Carcinoma		13		6%
MMMT		4		2%
Undifferentiated		2		1%
Pathologic Stage
I		50		22%
II		18		8%
III		140		60%
IV		24		10%
Silberberg’s Grade
1		27		12%
2		28		12%
3		177		76%
Received Chemotherapy
No		16		7%
Yes		216		93%
Residual Disease
No		113		49%
Yes		119		51%
Persistent Disease
No		144		62%
Yes		88		38%
LHR-I
Negative		30		13%
Weak		24		10%
Moderate		26		11%
Strong		152		66%
LHR-P
0%		30		13%
1–50%		4		2%
>  50%		197		85%
Missing/LHR Intensity Negative		1
Tumor Histology	N	LHR Expression Intensity
		Negative	Weak	Moderate	Strong
Serous Carcinoma	160	16 (10%)	19 (12%)	16 (10%)	109 (68%)
Endometrioid Adenocarcinoma	21	3 (14%)	2 (10%)	3 (14%)	13 (62%)
Clear Cell Carcinoma	17	0 (0%)	0 (0%)	4 (24%)	13 (76%)
Mixed	15	4 (27%)	1 (7%)	3 (20%)	7 (47%)
Mucinous Carcinoma	13	6 (46%)	2 (15%)	0 (0%)	5 (38%)
MMMT	4	1 (25%)	0 (0%)	0 (0%)	3 (75%)
Undifferentiated	2	0 (0%)	0 (0%)	0 (0%)	2 (100%)